VC/PE/M&A. Healthcare Weekly(2018.01.22)

 Mon Jan 22 16:14:23 CST 2018 A- A+

本期内容概览

  • 重塑肿瘤稳态,Pandion Therapeutics完成5800万美元的A轮融资。
  • Pavmed认购超额,微创设备前景可期!
  • 西门子医疗收购Fast Track Diagnostics,分子诊疗市场形成更强合力。

私募融资 & IPO

1. 重塑肿瘤稳态,Pandion Therapeutics 5800万美元的A轮融,资革新传统?

概要:专注靶向免疫调节药物研发的Pandion Therapeutics近日浮现在公众眼前,随之而来的是5800万美元的A轮融资。本轮投资由Polaris和罗氏风投基金以及Versant Ventures共同领投。公司CEO是Anthony Coyle,他曾经是辉瑞的高级副总裁和MedImmune的全球生物制剂副总裁。曾在Biogen领导药物研发和免疫学研究的Jo Viney则担任公司的首席科学家。公司立志通过研发,改变传统的疗法,通过将药物留在肿瘤生发部位,发挥更持久的作用,从而重塑肿瘤系统的稳态。Coyle表示,这笔A轮融资能够帮助公司将药物研发从化合物推进到临床试验初期阶段,并最终到达人体试验阶段。公司将首先专攻炎性肠病和自身免疫性肝病,然后再考虑扩展到自身免疫性肾病以及I型糖尿病。

相关报道:

Pandion Therapeutics launches with $58M series A

Jan 18, 2018

Pandion Therapeutics, which is developing targeted immune modulator drugs, emerged from stealth mode with a $58 million series A. Anthony Coyle, formerly a senior vice president at Pfizer and global head of biologics at MedImmune, signed on as CEO, while Jo Viney, who previously headed drug discovery and immunology research at Biogen, joined as chief scientific officer. “The funding will allow us to take compounds into the clinic, through that initial proof of concept and clinical efficacy study in humans,” Coyle said. Pandion will first target inflammatory bowel disease and autoimmune liver disease, before expanding into autoimmune kidney disorders and Type 1 diabetes. Pandion expects to advance the pipeline, move into the clinic and demonstrate clinical efficacy over the next several years, Coyle said. “Pandion is positioned to shift the paradigm for treating inflammatory and autoimmune diseases as well as transplant recipients by developing therapeutic antibodies that act at the local site of disease, offering the potential for significantly improved therapeutic options beyond systemic immunosuppressive treatments,” said Alan Crane, entrepreneur partner at Polaris Partners, which founded and ponied up the initial seed funding for Pandion, in a statement. Polaris co-led the series A alongside Roche Venture Fund and Versant Ventures. Immunosuppressive treatments are used to dampen inappropriate inflammatory responses in autoimmune and inflammatory disease, but have obvious side effects such as an increased risk of infection or cancer. Pandion is looking to shift away from the systemic approach and create drugs that regulate the immune system in a localized manner to restore immune homeostasis, Coyle said. These drugs could drive more patients into disease remission and provoke a more durable response, he said. The company’s tech is built to design bispecific antibodies that bind to specific tissues at local sites of inflammation. The concept is translated from the immuno-oncology space, Coyle said, where tumors are observed to disarm the immune system to avoid being recognized and attacked.

Source: FierceBiotech

https://www.fiercebiotech.com/biotech/pandion-therapeutics-launches-58m-series-a

2. Pavmed增发认购超额,微创设备前景可期

概要:位于美国纽约的医疗设备公司Pavmed在今年1月19日通过包销公开发行了2,415,278股,每股价值1.80美元。公司宣布将给其股票承销商以能够购买最多额外362,292股的45天期权,从而弥补认购超额。通过发行股票筹资,Pavmed计划支持其研发业务及当前产品管线的开发。2015年,公司IPO;去年11月,Pavmed就其CarpX设备向FDA提交了510(k)申请,这是一种针对腕管综合征的微创治疗设备。

相关报道:

Pavmed prices $4.3m offering

Jan 19, 2018

Pavmed (NSDQ:PAVM) today priced an underwritten public offering of 2,415,278 shares of its common stock at $1.80 per share. The New York City-based company said it would grant the offering’s underwriters a 45-day option to buy up to 362,292 additional shares of common stock to cover over-allotments. Pavmed expects to bring in $3.9 million in net proceeds from the offering after discounts and commissions, which it plans to use for working capital and other general corporate purposes. Yesterday, Pavmed registered for a nearly $90 million offering, saying it plans to float the rights to buy up to 14.6 million units. The company said it would issue a single unit for each share of common stock. Each unit is slated to include one common share and a six-year Series Z warrant worth $2.25 per share, redeemable at $3 apiece. Pavmed plans to use the funds it raises from the offering to support its R&D efforts and the development of its current pipeline, according to the prospectus filed with the SEC. Last week, Pavmed cut the exercise price on the Series W warrants, from $2.50 to $2.00 apiece, its second price cut since late last year. Originally exercisable at $5.00 apiece, the company slashed the price in half last December.

In November, Pavmed filed a 510(k) application with the FDA for its CarpX device, which is designed to be a minimally-invasive treatment for carpal tunnel syndrome.

Source: MassDevice

https://www.massdevice.com/pavmed-prices-4-3m-offering/

并购

1. 西门子医疗收购Fast Track Diagnostics,分子诊疗市场形成更强合力

概要:西门子医疗近期宣布已经完成了对Fast Track Diagnostics(FTD)的收购,具体金额未透露。完成交易之后,FTD在卢森堡、马耳他和印度的分部以及约80名雇员都将纳入西门子医疗的业务。FTD生产一系列CE标示通过的传染病监测系统以及综合征面板,并将在这次交易后继续使用原来的公司名开展原先的业务。西门子医疗的分子诊疗带头人Fernando Beils表示,这次收购将使得双方在分子诊疗市场产生更好的合力。

相关报道:

Siemens Healthineers closes Fast Track Diagnostics buy

Jan 10, 2018

Siemens (NYSE:SI) Healthineers said today it completed its acquisition of Fast Track Diagnostics, marking the official date of the closing as December 19, 2017. With the acquisition, FTD’s sites in Luxembourg, Malta and India and its approximately 80 employee workforce will be folded into Siemens Healthineers business. FTD produces a range of CE Mark approved infectious disease detection tests and syndromic panels, and will continue to operate under the brand name Fast Track Diagnostics, Siemens said. “The closing of this deal enables both Siemens Healthineers and FTD—now joined as one—to more effectively address the evolving needs of the molecular diagnostics marketplace. It is an exciting time for us at Siemens Healthineers as we welcome the FTD community into our own,” Siemens molecular diagnostics head Fernando Beils said in a press release. Terms of the deal were not disclosed by Siemens. Last month, Siemens said it launched the Cardio dashboard application in its Siemens Healthineers cloud-based network of applications.

Source: MassDevice

https://www.massdevice.com/siemens-healthineers-closes-fast-track-diagnostics-buy/

*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。
收藏
扫描二维码,关注新浪医药(sinayiyao)公众号
360°纵览医药全局,365天放送新闻时事医药资讯轻松一览
精彩不容错过。
文章评论
肖恩大侠 华盖医疗基金董事总经理,北京。 毕业于北京大学工学院医学院(医学硕士)、北京大学法学院(法学硕士)。资浅PE从业人士。躬耕于太湖,游学至未名,当过医生,学过法律,改行至风险投资,喜好读书写作,经史文集,现代科技都甚喜欢,总是怀着理想,万一,实现了呢?欢迎交流医疗、文化、消费,欢迎交流一级市场、二级市场,欢迎交流国内及海外并购。 邮箱:shawn.shiqq.com
+订阅
印象笔记
有道云笔记
微信
二维码
意见反馈